| Identification | Back Directory | [Name]
AVICULARIN | [CAS]
572-30-5 | [Synonyms]
AVICULARIN
Fenicularin
Avicularoside
QUERCETIN-3-ARABINOSIDE
QUERCETIN-3-ARABINOSIDE hplc
Quercetin 3-α-L-arabinofuranoside
Quercetin 3-O-α-L-arabinofuranoside
Avicularin, 98%, from Polygonum aviculare L.
Avicularin(Quercetin 3-alpha-L-arabinofuranoside)
3,3′,4′,5,7-Pentahydroxyflavone 3-O-α-L-arabinofuranoside
3-(α-L-Arabinofuranosyloxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 3-(α-L-arabinofuranosyloxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one | [Molecular Formula]
C20H18O11 | [MDL Number]
MFCD00016749 | [MOL File]
572-30-5.mol | [Molecular Weight]
434.35 |
| Chemical Properties | Back Directory | [Melting point ]
207-208 °C | [Boiling point ]
855.4±65.0 °C(Predicted) | [density ]
1.86±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly, Sonicated), Ethanol (Slightly, Sonicated), Methanol (Slightly, Sonicated) | [form ]
neat | [pka]
6.17±0.40(Predicted) | [color ]
Pale Yellow to Light Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Quercetin-3-arabinoside can be used to prevent or treat degenerative brain disease. | [Definition]
ChEBI: A quercetin O-glycoside in which an alpha-L-arabinofuranosyl residue is attached at position 3 of quercetin via a glycosidic linkage. It is isolated particularly from Juglans regia and | [in vivo]
Avicularin (injected in articular cavity of the knee, 0.5-2 mg/kg, twice a week for 4 weeks) attenuates the development of OA (osteoarthritis) in ACLT-induced rats[4].
?
Avicularin (oral administration, 50 and 100 mg/kg, for 21 days) attenuates memory Impairment in rats with amyloid Beta-induced Alzheimer's disease[5].
| Animal Model: | ACLT (anterior cruciate ligament transection)-induced rats[4] | | Dosage: | 0.5, 1, 2 mg/kg | | Administration: | Injected into the articular cavity of the right knee, twice a week for 4 weeks. | | Result: | Alleviated the tibial subchondral osteolysis, reduces bone loss, and increases the bone mass of tibial subchondral bone.
Attenuated ECM degradation, the loss of Aggrecan and Collagen II in ACLT-induced rats.
Decreased the MMP3 and MMP13 protein level.
|
| Animal Model: | Rats with amyloid Beta-induced Alzheimer's disease[5] | | Dosage: | 25, 50, and 100 mg/kg | | Administration: | Oral administration, for 21 days | | Result: | Enhanced cognition activity, and reversed the effects of amyloid beta-induced inflammatory response and excessive oxidative stress. |
| [IC 50]
GLUT4; PPARγ; COX-2 |
|
|